2252 related articles for article (PubMed ID: 8291613)
1. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.
de Vries TJ; Quax PH; Denijn M; Verrijp KN; Verheijen JH; Verspaget HW; Weidle UH; Ruiter DJ; van Muijen GN
Am J Pathol; 1994 Jan; 144(1):70-81. PubMed ID: 8291613
[TBL] [Abstract][Full Text] [Related]
2. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
[TBL] [Abstract][Full Text] [Related]
3. Spitz naevi may express components of the plasminogen activation system.
Ferrier CM; Van Geloof WL; Straatman H; Van De Molengraft FJ; Van Muijen GN; Ruiter DJ
J Pathol; 2002 Sep; 198(1):92-9. PubMed ID: 12210068
[TBL] [Abstract][Full Text] [Related]
4. Studies on functional and structural role of urokinase receptor and other components of the plasminogen activation system in malignancy.
Weidle UH; Wöllisch E; Rønne E; Ploug M; Behrendt N; de Vries TJ; Quax PH; Verheijen JH; van Muijen GN; Ruiter DJ
Ann Biol Clin (Paris); 1994; 52(11):775-82. PubMed ID: 7747886
[TBL] [Abstract][Full Text] [Related]
5. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
de Vries TJ; Kitson JL; Silvers WK; Mintz B
Cancer Res; 1995 Oct; 55(20):4681-7. PubMed ID: 7553649
[TBL] [Abstract][Full Text] [Related]
6. Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions.
De Vries TJ; De Wit PE; Clemmensen I; Verspaget HW; Weidle UH; Bröcker EB; Ruiter DJ; Van Muijen GN
J Pathol; 1996 Jul; 179(3):260-5. PubMed ID: 8774480
[TBL] [Abstract][Full Text] [Related]
7. Human Co115 colon carcinoma cells potentiate the degradation of laminin mediated by tissue-type plasminogen activator.
Tran-Thang C; Vouillamoz D; Kruithof EK; Sordat B
J Cell Physiol; 1994 Nov; 161(2):285-92. PubMed ID: 7962113
[TBL] [Abstract][Full Text] [Related]
8. Decreased expression of both the low-density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor and its receptor-associated protein in late stages of cutaneous melanocytic tumor progression.
de Vries TJ; Verheijen JH; de Bart AC; Weidle UH; Ruiter DJ; van Muijen GN
Cancer Res; 1996 Mar; 56(6):1432-9. PubMed ID: 8640836
[TBL] [Abstract][Full Text] [Related]
9. Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression.
Robert C; Bolon I; Gazzeri S; Veyrenc S; Brambilla C; Brambilla E
Clin Cancer Res; 1999 Aug; 5(8):2094-102. PubMed ID: 10473092
[TBL] [Abstract][Full Text] [Related]
10. The plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis.
Sugiura Y; Ma L; Sun B; Shimada H; Laug WE; Seeger RC; DeClerck YA
Cancer Res; 1999 Mar; 59(6):1327-36. PubMed ID: 10096567
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activators and their inhibitor gene expression in cutaneous NF1-related neurofibromas.
Sirén V; Peltonen J; Vaheri A
Arch Dermatol Res; 2006 Mar; 297(9):421-4. PubMed ID: 16408192
[TBL] [Abstract][Full Text] [Related]
12. Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.
Schacke W; Beck KF; Pfeilschifter J; Koch F; Hattenbach LO
Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2799-805. PubMed ID: 12147618
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
[TBL] [Abstract][Full Text] [Related]
14. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
15. Expression and localization of the urokinase-type plasminogen activator receptor (uPAR) in the human placenta.
Nishida Y; Hayashi Y; Imai Y; Itoh H
Kobe J Med Sci; 1998 Feb; 44(1):31-43. PubMed ID: 9846056
[TBL] [Abstract][Full Text] [Related]
16. Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines.
Quax PH; van Leeuwen RT; Verspaget HW; Verheijen JH
Cancer Res; 1990 Mar; 50(5):1488-94. PubMed ID: 2105839
[TBL] [Abstract][Full Text] [Related]
17. Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation.
Feng Q; Liu Y; Liu K; Byrne S; Liu G; Wang X; Li Z; Ockleford CD
Placenta; 2000; 21(2-3):184-93. PubMed ID: 10736241
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.
Pyke C; Kristensen P; Ralfkiaer E; Grøndahl-Hansen J; Eriksen J; Blasi F; Danø K
Am J Pathol; 1991 May; 138(5):1059-67. PubMed ID: 1850957
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activators in nude mice xenotransplanted with human tumorigenic cells.
Colombi M; Bellotti D; De Petro G; Barlati S
Invasion Metastasis; 1995; 15(1-2):22-33. PubMed ID: 7672929
[TBL] [Abstract][Full Text] [Related]
20. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]